Key Points
- Director James Mulay sold 1,964 CG Oncology shares on June 15 at an average price of $60.12, bringing in about $118,076. After the sale, he retained 654 shares, a 75% reduction in his stake.
- The sale was made under a pre-arranged Rule 10b5-1 trading plan, and it follows a much larger April transaction in which Mulay sold 15,600 shares for about $1.14 million.
- CG Oncology shares were up 1.2% to $60.28, while the stock has received a Moderate Buy consensus rating from analysts with an average target price of $81.73.
CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 1,964 shares of the company's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $60.12, for a total value of $118,075.68. Following the sale, the director owned 654 shares in the company, valued at approximately $39,318.48. This represents a 75.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Mulay also recently made the following trade(s):
- On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00.
CG Oncology Stock Up 1.2%
Shares of CGON opened at $60.28 on Wednesday. The business's 50-day moving average price is $64.74 and its 200-day moving average price is $56.84. CG Oncology, Inc. has a twelve month low of $23.65 and a twelve month high of $75.50. The stock has a market cap of $5.32 billion, a PE ratio of -25.87 and a beta of 0.31.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to analysts' expectations of $0.45 million. Analysts expect that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.
Institutional Investors Weigh In On CG Oncology
Institutional investors and hedge funds have recently bought and sold shares of the stock. NFSG Corp purchased a new stake in CG Oncology in the first quarter valued at approximately $34,000. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology during the fourth quarter valued at approximately $27,000. Comerica Bank grew its position in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company's stock valued at $43,000 after acquiring an additional 515 shares during the last quarter. Fifth Third Bancorp bought a new position in CG Oncology during the first quarter valued at approximately $74,000. Finally, KBC Group NV bought a new position in CG Oncology during the first quarter valued at approximately $78,000. 26.56% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
CGON has been the topic of several analyst reports. Wall Street Zen cut CG Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, April 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CG Oncology in a research note on Monday, April 20th. JPMorgan Chase & Co. raised their target price on shares of CG Oncology from $91.00 to $96.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Wolfe Research started coverage on shares of CG Oncology in a research note on Tuesday, May 19th. They issued a "peer perform" rating on the stock. Finally, Wedbush raised their target price on shares of CG Oncology from $77.00 to $80.00 and gave the company an "outperform" rating in a research note on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.73.
View Our Latest Report on CG Oncology
CG Oncology Company Profile
(
Get Free Report)
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
